Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 7 von 69
Journal of epidemiology and community health (1979), 2011-08, Vol.65 (Suppl 1), p.A240-A241
2011
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
P2-76 Antibiotics for hepatic encephalopathy: systematic review of randomised controlled trials
Ist Teil von
  • Journal of epidemiology and community health (1979), 2011-08, Vol.65 (Suppl 1), p.A240-A241
Ort / Verlag
London: BMJ Publishing Group Ltd
Erscheinungsjahr
2011
Quelle
BMJ Journals Archiv - DFG Nationallizenzen
Beschreibungen/Notizen
  • ObjectiveTo assess the effectiveness of antibiotics in the treatment of hepatic encephalopathy (HE).Data sourcesCochrane Hepato-Biliary Group controlled trials register, Cochrane Controlled Trials Register, MEDLINE, LILACS, SCI Expanded, Embase and http://clinicaltrials.gov/ until January 2010; reference lists of relevant articles and authors were searched.Review methodsThe methodological approach outlined in the Cochrane Handbook was followed. Randomised trials comparing antibiotics with placebo, no intervention, non-absorbable disaccharides, another antibiotic or any other active treatment for HE were included. The primary outcome measures were no improvement of HE and all-cause mortality.ResultsTwenty-eight studies were included in this review; most had a small sample size and were methodologically of a low quality. Two studies (N=132) compared antibiotics with placebo or no intervention, reporting no differences in primary outcomes between groups. Twelve studies (N=708) compared antibiotics with non-absorbable disaccharides, reporting no difference in all-cause mortality (RR=1.11 (95% CI 0.60 to 2.07)) but a marginally significant reduction in the risk of “no improvement” (RR 0.83 (0.69 to 1.00)). In sensitivity analysis, this finding was significant in trials evaluating chronic encephalopathy (RR 0.50 (0.28 to 0.89)) and in trials with co-administration of cathartic agents (RR 0.82 (0.67 to 0.99)). Ten trials (N=336), compared different antibiotic regimens, most evaluating rifaximin and neomycin. Rifaximin reduced the risk of no improvement compared to neomycin, but not significantly so (RR 0.61 (0.34 to 1.09)).ConclusionsInsufficient evidence exists to support or refute the use of antibiotics for HE. Antibiotics were slightly superior to non-absorbable disaccharides at improving HE, with borderline significance and possible effect modification.
Sprache
Englisch
Identifikatoren
ISSN: 0143-005X
eISSN: 1470-2738
DOI: 10.1136/jech.2011.142976i.11
Titel-ID: cdi_proquest_miscellaneous_899139860

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX